|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-4-1
|
|
pubmed:abstractText |
Vandetanib (ZACTIMA) is a once-daily, oral anticancer drug that selectively inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling. Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:EguchiKenjiK,
pubmed-author:FukuokaMasahiroM,
pubmed-author:JiangHaiyiH,
pubmed-author:KiuraKatsuyukiK,
pubmed-author:NakagawaKazuhikoK,
pubmed-author:NishioKazutoK,
pubmed-author:OheYuichiroY,
pubmed-author:SaijoNagahiroN,
pubmed-author:SetoTakashiT,
pubmed-author:ShinkaiTetsuT,
pubmed-author:TsuboiMasahiroM,
pubmed-author:YamamotoNobuyukiN,
pubmed-author:YokotaSoichiroS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
386-93
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18379357-Adenocarcinoma,
pubmed-meshheading:18379357-Administration, Oral,
pubmed-meshheading:18379357-Adult,
pubmed-meshheading:18379357-Aged,
pubmed-meshheading:18379357-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18379357-Carcinoma, Squamous Cell,
pubmed-meshheading:18379357-Double-Blind Method,
pubmed-meshheading:18379357-Female,
pubmed-meshheading:18379357-Humans,
pubmed-meshheading:18379357-Japan,
pubmed-meshheading:18379357-Lung Neoplasms,
pubmed-meshheading:18379357-Male,
pubmed-meshheading:18379357-Maximum Tolerated Dose,
pubmed-meshheading:18379357-Middle Aged,
pubmed-meshheading:18379357-Mutation,
pubmed-meshheading:18379357-Neoplasm Recurrence, Local,
pubmed-meshheading:18379357-Piperidines,
pubmed-meshheading:18379357-Prognosis,
pubmed-meshheading:18379357-Quinazolines,
pubmed-meshheading:18379357-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18379357-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
|
|
pubmed:affiliation |
Okayama Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital, Okayama, Japan. kkiura@md.okayama-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
